| P50 | author | Adriaan Cleton | Q72784185 |
| P2093 | author name string | Joris Berwaerts | |
| | Bart Remmerie | |
| | An Vandebosch | |
| | Virginie Kerbusch-Herben | |
| P2860 | cites work | A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. | Q52064577 |
| | Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine | Q56791101 |
| | Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia | Q71502070 |
| | Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction | Q73148551 |
| | Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study | Q73193644 |
| | Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study | Q73370933 |
| | A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism | Q77708447 |
| | The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers | Q24564995 |
| | A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects | Q34397398 |
| | Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements | Q34547632 |
| | Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics | Q34563883 |
| | Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. | Q34742844 |
| | Pharmacokinetic interactions of topiramate | Q35881745 |
| | Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia | Q36873906 |
| | Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia | Q37110991 |
| | The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 |
| | Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays | Q43097869 |
| | No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects | Q43289205 |
| | Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes | Q44055483 |
| | Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry | Q44249410 |
| | P-glycoprotein-mediated intestinal and biliary digoxin transport in humans | Q44351189 |
| | Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. | Q45062160 |
| | Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine | Q46525558 |
| | Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice | Q46829249 |
| P433 | issue | 5 | |
| P921 | main subject | carbamazepin | Q410412 |
| P304 | page(s) | 371-377 | |
| P577 | publication date | 2014-05-26 | |
| P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
| P1476 | title | Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state | |
| P478 | volume | 3 | |